MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ellis, J.
Right arrow Articles by Brann, M. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ellis, J.
Right arrow Articles by Brann, M. R.

Use of chimeric muscarinic receptors to investigate epitopes involved in allosteric interactions

J Ellis, M Seidenberg and MR Brann

Department of Psychiatry, University of Vermont, Burlington 05405.

All five (m1-m5) muscarinic receptors are sensitive to allosteric regulation, but gallamine is considerably more potent in slowing the dissociation of N-[3H]methylscopolamine (NMS) from the m2 subtype than from the m3 or m5 subtypes. To study the structural basis for the preference of gallamine for the m2 subtype, we evaluated [3H]NMS- gallamine interactions with chimeric receptors in which segments of the m5 receptor were systematically replaced with the corresponding m2 sequence. Substitutions that included the sixth transmembrane domain and third extracellular loop resulted in marked increases in the potency of gallamine, but substitutions that did not include these regions were without effect. A similar substitution was investigated using m2/m3 chimeric receptors, in which a segment extending from the middle of the sixth transmembrane domain to the carboxyl terminus was exchanged. As with the m2/m5 constructs, substitution of the m2 carboxyl-terminal segment into the m3 subtype significantly increased the potency of gallamine. Furthermore, the converse substitution reduced the potency of gallamine dramatically, to approximately that seen for the m3 subtype itself. It appears that this portion of the receptor is a critical determinant for the binding of gallamine and/or the allosteric interactions between gallamine and [3H]NMS.

Volume 44, Issue 3, pp. 583-588, 09/01/1993
Copyright © 1993 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
D. S. Redka, L. F. Pisterzi, and J. W. Wells
Binding of Orthosteric Ligands to the Allosteric Site of the M2 Muscarinic Cholinergic Receptor
Mol. Pharmacol., September 1, 2008; 74(3): 834 - 843.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
T. Steinfeld, M. Mammen, J. A. M. Smith, R. D. Wilson, and J. R. Jasper
A Novel Multivalent Ligand That Bridges the Allosteric and Orthosteric Binding Sites of the M2 Muscarinic Receptor
Mol. Pharmacol., August 1, 2007; 72(2): 291 - 302.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
X.-P. Huang and J. Ellis
Mutational Disruption of a Conserved Disulfide Bond in Muscarinic Acetylcholine Receptors Attenuates Positive Homotropic Cooperativity between Multiple Allosteric Sites and Has Subtype-Dependent Effects on the Affinities of Muscarinic Allosteric Ligands
Mol. Pharmacol., March 1, 2007; 71(3): 759 - 768.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
S. Prilla, J. Schrobang, J. Ellis, H.-D. Holtje, and K. Mohr
Allosteric Interactions with Muscarinic Acetylcholine Receptors: Complex Role of the Conserved Tryptophan M2422Trp in a Critical Cluster of Amino Acids for Baseline Affinity, Subtype Selectivity, and Cooperativity
Mol. Pharmacol., July 1, 2006; 70(1): 181 - 193.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
C. Fruchart-Gaillard, G. Mourier, C. Marquer, A. Menez, and D. Servent
Identification of Various Allosteric Interaction Sites on M1 Muscarinic Receptor Using 125I-Met35-Oxidized Muscarinic Toxin 7
Mol. Pharmacol., May 1, 2006; 69(5): 1641 - 1651.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
X.-P. Huang, S. Prilla, K. Mohr, and J. Ellis
Critical Amino Acid Residues of the Common Allosteric Site on the M2 Muscarinic Acetylcholine Receptor: More Similarities than Differences between the Structurally Divergent Agents Gallamine and Bis(ammonio)alkane-Type Hexamethylene-bis-[dimethyl-(3-phthalimidopropyl)ammonium]dibromide
Mol. Pharmacol., September 1, 2005; 68(3): 769 - 778.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
J. Jakubik, A. Krejci, and V. Dolezal
Asparagine, Valine, and Threonine in the Third Extracellular Loop of Muscarinic Receptor Have Essential Roles in the Positive Cooperativity of Strychnine-Like Allosteric Modulators
J. Pharmacol. Exp. Ther., May 1, 2005; 313(2): 688 - 696.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
U. Voigtlander, K. Johren, M. Mohr, A. Raasch, C. Trankle, S. Buller, J. Ellis, H.-D. Holtje, and K. Mohr
Allosteric Site on Muscarinic Acetylcholine Receptors: Identification of Two Amino Acids in the Muscarinic M2 Receptor That Account Entirely for the M2/M5 Subtype Selectivities of Some Structurally Diverse Allosteric Ligands in N-Methylscopolamine-Occupied Receptors
Mol. Pharmacol., July 1, 2003; 64(1): 21 - 31.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
C. Trankle, O. Weyand, U. Voigtlander, A. Mynett, S. Lazareno, N. J. M. Birdsall, and K. Mohr
Interactions of Orthosteric and Allosteric Ligands with [3H]Dimethyl-W84 at the Common Allosteric Site of Muscarinic M2 Receptors
Mol. Pharmacol., July 1, 2003; 64(1): 180 - 190.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
S. Buller, D. P. Zlotos, K. Mohr, and J. Ellis
Allosteric Site on Muscarinic Acetylcholine Receptors: A Single Amino Acid in Transmembrane Region 7 Is Critical to the Subtype Selectivities of Caracurine V Derivatives and Alkane-Bisammonium Ligands
Mol. Pharmacol., January 1, 2002; 61(1): 160 - 168.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
A. Krejci and S. Tucek
Changes of Cooperativity between N-Methylscopolamine and Allosteric Modulators Alcuronium and Gallamine Induced by Mutations of External Loops of Muscarinic M3 Receptors
Mol. Pharmacol., October 1, 2001; 60(4): 761 - 767.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
J. Ellis and M. Seidenberg
Interactions of Alcuronium, TMB-8, and Other Allosteric Ligands with Muscarinic Acetylcholine Receptors: Studies with Chimeric Receptors
Mol. Pharmacol., April 13, 2001; 58(6): 1451 - 1460.
[Abstract] [Full Text]


Home page
Mol. Pharmacol.Home page
A. L. Gnagey, M. Seidenberg, and J. Ellis
Site-Directed Mutagenesis Reveals Two Epitopes Involved in the Subtype Selectivity of the Allosteric Interactions of Gallamine at Muscarinic Acetylcholine Receptors
Mol. Pharmacol., December 1, 1999; 56(6): 1245 - 1253.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
J. Jakubik and J. Wess
Use of a Sandwich Enzyme-linked Immunosorbent Assay Strategy to Study Mechanisms of G Protein-coupled Receptor Assembly
J. Biol. Chem., January 15, 1999; 274(3): 1349 - 1358.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
M. P. Caulfield and N. J. M. Birdsall
International Union of Pharmacology. XVII. Classification of Muscarinic Acetylcholine Receptors
Pharmacol. Rev., June 1, 1998; 50(2): 279 - 290.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
C. Tränkle, I. Andresen, G. Lambrecht, and K. Mohr
M2 Receptor Binding of the Selective Antagonist AF-DX 384: Possible Involvement of the Common Allosteric Site
Mol. Pharmacol., February 1, 1998; 53(2): 304 - 312.
[Abstract] [Full Text]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1993 by the American Society for Pharmacology and Experimental Therapeutics